Please see the exciting press release from Sangamo Therapeutics below.
Click here to download the press release
Here is a small expert:
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway
Isaralgagene civaparvovec continues to show favorable safety and tolerability profile
Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval pathway in second quarter of 2026